Affordable Access

Publisher Website

TNF regulates sialyl-Lewisx and 6-sulfo-sialyl-Lewisx expression in human lung through up-regulation of ST3GAL4 transcript isoform BX

Authors
Journal
Biochimie
0300-9084
Publisher
Elsevier
Volume
94
Issue
9
Identifiers
DOI: 10.1016/j.biochi.2012.05.030
Keywords
  • Inflammation
  • St3Gal4
  • Terminal Glycosylation
  • Transcriptional Regulation
  • Cystic Fibrosis
Disciplines
  • Biology
  • Computer Science
  • Medicine

Abstract

Abstract Bronchial mucins from severely infected patients suffering from lung diseases such as chronic bronchitis or cystic fibrosis exhibit increased amounts of sialyl-Lewisx (NeuAcα2-3Galβ1-4[Fucα1-3]GlcNAc-R, sLex) glycan structures. In cystic fibrosis, sLex and its sulfated form 6-sulfo-sialyl-Lewisx (NeuAcα2-3Galβ1-4[Fucα1-3](HO3S-6)GlcNAc-R, 6-sulfo-sLex) serve as receptors for Pseudomonas aeruginosa and are involved in the chronicity of airway infection. However, little is known about the molecular mechanisms regulating the changes in glycosylation and sulfation of mucins in airways. Herein, we show that the pro-inflammatory cytokine TNF increases the expression of α2,3-sialyltransferase gene ST3GAL4, both in human bronchial mucosa and in A549 lung carcinoma cells. The role of sialyltransferase ST3Gal IV in sLex biosynthesis was confirmed by siRNA silencing of ST3GAL4 gene. BX is the major transcript isoform expressed in healthy bronchial mucosa and in A549 cells, and is up-regulated by TNF in both models. Bioinformatics analysis and luciferase assays have confirmed that the 2 kb genomic sequence surrounding BX exon contains a promoter region regulated by TNF-related transcription factors. These results support further work aiming at the development of anti-inflammatory strategy to reduce chronic airway infection in diseases such as cystic fibrosis.

There are no comments yet on this publication. Be the first to share your thoughts.